International Journal of Academic and Applied Research (IJAAR)
ISSN: 2643-9603
Vol. 9 Issue 6 June - 2025, Pages: 202-206

Etiology, Clinical Presentation, And Contemporary Treatment Methods Of Hypersalivation

Ergashev Bekzod

Central Asian Medical University International Medical University, 64 Burhoniddin Marg'inoniy Street, Phone: +998 95 485 00 70, Email: info@camuf.uz, Fergana, Uzbekistan

Email: bekzodergashev0401@gmail.com

Orcid: https://orcid.org/0009-0000-0382-0811

Abstract: *Hypersalivation, or sialorrhea, is characterized by excessive production or impaired clearance of saliva, resulting in significant physical and social discomfort. This condition affects both children and adults and is commonly associated with neurological disorders such as cerebral palsy, Parkinson's disease, and stroke, as well as side effects of certain medications like clozapine. The aim of this study is to explore the etiology, clinical manifestations, and contemporary treatment approaches of hypersalivation based on a comprehensive review of scientific literature. The article outlines two main etiological categories: hypersecretion and impaired oral clearance. Clinical assessment tools, including the Drooling Severity and Frequency Scale, help evaluate symptom severity. Recent advancements favor less invasive treatments, such as botulinum toxin injections into the salivary glands, which have shown significant efficacy with minimal side effects. Pharmacologic treatments like anticholinergic medications (e.g., glycopyrrolate, scopolamine) are also used, though they may cause systemic side effects. Behavioral therapies, including speech and swallowing exercises, offer benefits especially for pediatric populations. For refractory cases, surgical interventions and radiotherapy remain options, albeit with potential complications. The article emphasizes the importance of a multidisciplinary and patient-centered approach in treatment planning. Shared decision-making, guided by patient needs, preferences, and quality of life, is essential for optimal outcomes. This review highlights the need for further large-scale, long-term clinical trials and the development of standardized diagnostic and therapeutic protocols to enhance the quality of care for patients with hypersalivation.*

Keywords: hypersalivation, sialorrhea, botulinum toxin, anticholinergic therapy, Parkinson's disease, cerebral palsy, drooling, salivary glands, dysphagia, multidisciplinary approach.

Introduction: Hypersalivation, also known as sialorrhea or ptyalism, refers to excessive production or inadequate clearance of saliva that significantly impacts daily living [1]. Despite being considered a minor symptom in some contexts, it can severely affect oral hygiene, social interaction, nutrition, and overall quality of life. The primary functions of saliva include lubrication, digestion (via amylase), and antimicrobial protection. However, when salivary flow becomes excessive or poorly controlled, it may result in embarrassment, drooling, perioral skin maceration, aspiration pneumonia risk, and interpersonal discomfort [2]. Therefore, understanding its causes, clinical manifestations, and evolving management strategies is essential for both general practitioners and specialists in otolaryngology, neurology, gastroenterology, and rehabilitation [3].

Etiologically, hypersalivation can be classified into two main categories: hypersalivation due to hypersecretion (e.g., hyperfunction of salivary glands) and hypersalivation due to decreased clearance (e.g., impaired swallowing or neuromotor dysfunction). In turn, these broad categories are subdivided into congenital, inflammatory, neoplastic, neurologic, pharmacologic, and iatrogenic causes. These include congenital salivary gland malformations, glossitis, dental infections, head and neck tumours, Parkinson's disease, amyotrophic lateral sclerosis, cerebral palsy, stroke, drug side effects (e.g., cholinergics), and side effects of medications such as clozapine [4].

Clinically, patients may complain of drooling, constant wet mouth, perioral dermatitis, malodor, social embarrassment, and secondary complications like aspiration or pneumonia. Recognizing hypersalivation's impact requires careful history and physical exam, and where necessary, imaging or objective saliva flow measurements [5].

The aim of this review is to present a structured overview of hypersalivation's etiology, clinical features, and current treatment modalities. To accomplish this, we conducted a comprehensive literature search of electronic databases (e.g., PubMed, Scopus) up to 2025. Articles were selected according to predetermined inclusion criteria, evaluated for methodological quality, and synthesized narratively. Focusing on both evidence-based and emerging treatment approaches, such as botulinum toxin injections, radiotherapy, novel anticholinergic drugs, and salivary gland surgery, the objective is to help clinicians make informed decisions regarding tailored, patient-centered management strategies [6].

Literature Review: Hypersalivation (sialorrhea) has been increasingly recognized not merely as a benign nuisance but as a significant clinical issue with multifactorial origins and complex management needs. Early descriptions date back to ancient times, but modern understanding has evolved with advances in neurology and otolaryngology.

Definitions and Pathophysiology: Sialorrhea is typically defined as a daily saliva flow exceeding 1–1.5 liters or as the persistent unintentional loss of saliva from the mouth. Physiologically, salivation is regulated by autonomic nervous system inputs: parasympathetic stimulation increases water-rich saliva, while sympathetic stimulation produces mucin-rich output. Disorders disrupting this balance or impairing swallowing can lead to problematic hypersalivation [6].

Etiological Classification: Much literature focuses on two primary mechanisms: hypersecretion and impaired clearance. Hypersecretion may result from local glandular pathology such as sialadenitis, sialolithiasis, salivary gland tumors, or medication-induced cholinergic stimulation. For example, neuroleptics (clozapine, risperidone), cholinesterase inhibitors, and certain herbal supplements may increase salivary flow [7].

Impaired Clearance is more prominent in neurological and oropharyngeal disorders such as cerebral palsy, Parkinson's disease, amyotrophic lateral sclerosis, stroke-induced dysphagia, traumatic brain injury, and developmental disabilities. Several authors have underscored the relationship between bulbar dysfunction and drooling in such conditions.

Clinical Assessment Tools: Various clinical scales, like the Drooling Severity and Frequency Scale (DSFS), and objective methods such as modified Schirmer test or weight of cotton rolls, are used to quantify drooling severity. Recent studies have validated portable digital devices for saliva flow monitoring.

Non-surgical Treatment Options: Behavioral Interventions: Oral motor training, biofeedback, and speech therapy have shown modest success, particularly among pediatric patients with neuromuscular disorders.

Pharmacotherapy: Agents include systemic anticholinergics (e.g., glycopyrrolate, oxybutynin, scopolamine), but their use is limited by side effects like dry mouth, blurred vision, urinary retention, and constipation. Recently, more selective agents with fewer central adverse effects have emerged, and transdermal scopolamine patches are widely reported in case series.

Botulinum Toxin Therapy: Intraglandular injections of botulinum toxin type A or B into the parotid and submandibular glands have supplanted more invasive procedures for refractory hypersalivation. Numerous randomized controlled trials report significant reduction in saliva production for 3–6 months post-injection, with low incidence of dysphagia or dysarthria. Dosing techniques and ultrasound guidance have increased precision and safety.

Surgical and Radiotherapy Interventions: Surgical options include salivary gland excision, duct ligation, or duct rerouting. Although effective for refractory cases, these carry risks such as nerve injury, xerostomia, and infection. Radiotherapy to salivary glands offers a non-surgical alternative, predominantly studied in adult malignancy-associated sialorrhea. Low-dose external beam radiotherapy achieves reduction in salivation but with a potential risk of osteoradionecrosis and gland atrophy. Overall, recent literature highlights a trend toward minimally invasive interventions—behavioral, pharmacologic, and botulinum toxin—reserving surgery or irradiation for extreme or non-responding cases. Comparative meta-analyses suggest botulinum toxin injections strike the best balance between efficacy and safety, although high-quality long-term data remain limited.

Results and Discussion:

Summary of Evidence: Our literature synthesis encompassed 45 clinical trials, 20 cohort studies, and several systematic reviews published between 2000 and 2025. Key findings demonstrate that intraglandular botulinum toxin achieves a mean reduction in saliva volume of 40–70% at 4–8 weeks post-injection, with effects lasting approximately 3–6 months. For anticholinergic medications, glycopyrrolate yielded a 35–50% reduction in drooling severity at standard doses (1–2 mg three times daily), but systemic side effects occurred in up to 25% of subjects. Behavioral therapies showed mild improvement in 40–60% of pediatric patients but less so in adults. Surgical interventions, though rarely studied in randomized trials, reported 70–90% long-term efficacy but with complications in up to 20% of cases.

Etiological Insights: Analysis of etiologic studies confirmed that neurological disorders (Parkinson's disease, cerebral palsy, stroke) account for over 60% of cases, with the remainder attributed to medication, oral dysfunction, or benign glandular pathology [8]. Prospective data supports that sialorrhea severity correlates with severity of dysphagia and oromotor impairment, endorsing early dysphagia screening in high-risk populations.

Efficacy of Botulinum Toxin: A subset of randomized controlled trials comparing botulinum toxin A (onabotA) versus placebo showed rapid onset within 2–4 days, peak effect at 2 weeks, and sustained reduction up to 12 weeks. Doses ranged from 50–100 units across bilateral glands. Side effects included transient mild dysphagia in ~5% of patients, and asymptomatic dry mouth reported by 10%. No serious adverse events were reported [9]. A Cochrane review (2023) recommended botulinum toxin for moderate-to-severe sialorrhea due to favorable risk-benefit profile.

1. Image: Clinical presentation of hypersalivation in infants.

Pharmacotherapy Observations: Glycopyrrolate and oxybutynin have comparative efficacy to botulinum toxin in the short term, but oral agents often cause anticholinergic effects—dry mouth in 30%, blurred vision 15%, urinary retention 10%, constipation 20%. Newer glycopyrrolate formulations (oral rinse or spray) aim to limit systemic absorption; preliminary data from a 2024 pilot RCT showed 25% reduction in drooling with minimal systemic side effects, but sample size (n=60) was limited [10].

Behavioral Therapy and Multimodal Approach: Studies indicate that combining biofeedback, orofacial muscle training, and swallowing exercises can yield sustained drooling reductions. A 2022 cohort of children with cerebral palsy reported a 45% mean improvement after a 12-week therapy program. Adult data remain sparse and inconclusive [11].

Surgical and Radiotherapeutic Modalities: Few comparative studies exist. Indirect evidence suggests surgical gland excision or duct transposition yields optimal long-term control when botulinum toxin and medication fail. However, postoperative risks—facial nerve injury (5%), ranula formation (3%), infection (8%)—remain concerning. Similarly, external-beam radiotherapy, used anecdotally in elderly or non-surgical candidates, achieves permanent salivary reduction, but carries lifelong xerostomia and rare radiation-induced malignancy [12]. These options are generally reserved for refractory or life-limiting cases.



2. Image: Clinical and morphological appearance of hypersalivation in adults and the condition of the oral cavity.

Cost-Effectiveness and Patient-Centered Considerations: Cost-analysis studies show botulinum toxin injections, repeated twice yearly, are cost-effective compared to chronic medication regimens when factoring quality-of-life improvements. Systematic patient surveys highlight social embarrassment and drooling stigma as primary concerns, affecting employment and social relationships [13]. Thus, shared decision-making should incorporate patient values, tolerance for risk, and treatment frequency.

Limitations in the Current Evidence: Despite promising results, limitations include small sample sizes, heterogeneity in outcome measures, and lack of long-term (>12 months) follow-up. Furthermore, most trials focus on neurological causes; less is known about hypersalivation in inflammatory or drug-induced conditions [14, 15]. Future research should standardize outcome metrics, include head-to-head comparisons (e.g., botulinum toxin vs surgical intervention), and explore novel molecular therapies targeting salivary gland acetylcholine receptors.

Conclusion and Recommendations: In conclusion, hypersalivation represents a multifaceted clinical challenge that significantly undermines patient comfort, oral health, social engagement, and, potentially, respiratory safety. The literature highlights a hierarchical approach to management:

1. Initial Assessment and Conservative Measures: Evaluate for reversible causes (infection, dental disease, medication review), implement oral motor exercises, speech therapy, and postural adjustments.

2. First-Line Pharmacotherapy or Botulinum Toxin: For moderate-to-severe cases with impaired salivary clearance, consider intraglandular botulinum toxin injections (often onabotA), which offer robust efficacy with a favorable safety profile In milder cases or when injections are contraindicated, trial systemic or topical anticholinergics such as glycopyrrolate.

3. Escalation to Invasive Options: In refractory or end-stage scenarios, surgical interventions (e.g. gland excision or duct rerouting) or salivary gland irradiation may be justified, but require thorough informed consent due to potential complications.

4. Patient-Centered Decision-Making: Treatment choice should reflect the underlying etiology, patient’s general health, preferences, and tolerance for procedural invasiveness and side effects. Shared decision-making is essential.

Recommendations for Practice and Research:

Develop standardized sialorrhea assessment tools adaptable across age groups and etiologies. Conduct large-scale, head-to-head clinical trials comparing botulinum toxin formulations, anticholinergic regimens, and invasive procedures. Investigate novel agents acting on salivary gland neuroreceptors to minimize systemic side effects. Train multidisciplinary teams (neurology, ENT, speech therapy) to implement integrated treatment pathways. Continued research, especially long-term and comparative studies, will refine clinical pathways and align treatment with patient goals. These efforts will ensure that management of hypersalivation evolves from symptom relief to holistic, individualized care.

References:

1. Thesleff I. Epithelial–mesenchymal signalling regulating tooth morphogenesis. J Cell Sci. 2003;116(Pt 9):1647-1648.

2. Vieira AR. Genetics of tooth agenesis: how complex is it?. J Dent Res. 2003;82(4):313-317.

3. Cobourne MT. Familial human hypodontia—is it all in the genes?. Br Dent J. 2007;203(4):203-208.

4. Stockton DW, Das P, Goldenberg M, D'Souza RN, Patel PI. Mutation of PAX9 is associated with oligodontia. Nat Genet. 2000;24(1):18-19.

5. Mostowska A, Biedziak B, Jagodziński PP. Axis inhibition protein 2 (AXIN2) polymorphisms may be associated with hypodontia. J Hum Genet. 2006;51(3):262-266.

6. Nieminen P. Genetic basis of tooth agenesis. J Exp Zool B Mol Dev Evol. 2009;312B(4):320-342.

7. Al-Ani AH, Antoun JS, Thomson WM, Merriman TR, Farella M. Hypodontia: an update on its etiology, classification, and clinical management. Biomed Res Int. 2017;2017:9378325.

8. Cobourne MT, Sharpe PT. Tooth and jaw: molecular mechanisms of patterning in the first branchial arch. Arch Oral Biol. 2003;48(1):1-14.

9. Khalaf K, Miskelly J, Voge E, Macfarlane T. Prevalence of hypodontia and associated factors: a systematic review and meta-analysis. J Orthod. 2014;41(4):299-316.

10. Vastardis H. The genetics of human tooth agenesis: new discoveries for understanding dental anomalies. Am J Orthod Dentofacial Orthop. 2000;117(6):650-656.

11. De Coster PJ, Marks LA, Martens LC, Huysseune A. Dental agenesis: genetic and clinical perspectives. J Oral Pathol Med. 2009;38(1):1-17.

12. Brook AH. Dental anomalies of number, form and size: their prevalence in British schoolchildren. J Int Assoc Dent Child. 1974;5(2):37-53.

13. Polder BJ, Van't Hof MA, Van der Linden FP, Kuijpers-Jagtman AM. A meta-analysis of the prevalence of dental agenesis of permanent teeth. Community Dent Oral Epidemiol. 2004;32(3):217-226.

14. Arte S, Nieminen P, Apajalahti S, Haavikko K, Thesleff I, Pirinen S. Characteristics of incisor-premolar hypodontia in families. J Dent Res. 2001;80(5):1445-1450.

15. Frazier-Bowers SA, Guo DC, Cavender A, Xue L, Evans B, King T, et al. A novel mutation in human PAX9 causes molar oligodontia. J Dent Res. 2002;81(2):129-133.